ReNeuron regains rights to hRPC technology; looking for new partner
Having only in July announced an agreement with an unnamed US biopharma company for its hRPC retinal stem cell technology and therapeutic programs, shares of UK cell-based therapies company ReNeuron (AIM: RENE) plunged nearly 20% to 65.00 pence by early afternoon today, when it revealed that the American firm has pulled out of the deal.
The US company has now informed ReNeuron that it no longer wishes to progress to a definitive licensing agreement. Importantly, the US company’s decision is not related to the hRPC technology itself or to the data generated with the hRPC platform but is instead specific to the US company. ReNeuron’s management therefore believes that the company’s prospects for licensing its hRPC technology and programs remain strong.
Will resume discussions with other interested parties
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze